SCHEMBL4240897

SCHEMBL4240897

CN(CC1C2CCC1CN(Cc1ccccc1)C2)C(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
ALDH1A1 P00352 1/20 0.54
MLNR O43193 2/20 0.48
CYP3A4 P08684 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.45
TACR1 P25103 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
ACHE P22303 2/20 0.41
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
KDM2B Q8NHM5 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
BCHE P06276 1/20 0.40
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241259 0.84 CHRM4 (0.54) ACHECHRM4
SCHEMBL4245945 0.79 USP30 (0.54) MLNRCYP3A4S1PR1S1PR5CHRM4
SCHEMBL4237299 0.78 CHRNB2 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2HCRTR1
SCHEMBL4250553 0.76 ACHE (0.46) ACHES1PR1S1PR5
SCHEMBL3226713 0.72 CHRM3 (0.51) ALDH1A1
SCHEMBL4244909 0.72 S1PR1 (0.44) MEN1KMT2AALDH1A1MLNRCYP3A4
SCHEMBL4198217 0.71 FUCA1 (0.54) ALDH1A1ACHES1PR1S1PR5BCHE
SCHEMBL4246478 0.70 TACR1 (0.49) MEN1KMT2AALDH1A1TACR1
SCHEMBL7242578 0.70 FUCA1 (0.50) SMN1; SMN2ACHES1PR1S1PR5BCHE
SCHEMBL4244157 0.70 GRIN2B (0.41) ACHES1PR1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US claimed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP claimed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US disclosed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012116-A1 Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 MEN1 1950/4885KMT2A 2913/4885ALDH1A1 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.